155 related articles for article (PubMed ID: 36034977)
1. Cost-effectiveness of olaparib, a PARP inhibitor, for patients with metastatic castration-resistant prostate cancer in China and United States.
Xu C; Cai J; Zhuang J; Zheng B; Chen L; Sun H; Zheng G; Wei X; Liu M
Ann Transl Med; 2022 Aug; 10(15):830. PubMed ID: 36034977
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Su D; Wu B; Shi L
Front Pharmacol; 2020; 11():610601. PubMed ID: 33574757
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance.
Barqawi YK; Borrego ME; Roberts MH; Abraham I
J Med Econ; 2019 Nov; 22(11):1202-1209. PubMed ID: 31452414
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china.
Shu Y; Liu Y; He X; Ding Y; Zhang Q
Front Pharmacol; 2022; 13():818579. PubMed ID: 36034834
[No Abstract] [Full Text] [Related]
5. Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic
Li N; Zheng H; Huang Y; Zheng B; Cai H; Liu M
Front Pharmacol; 2021; 12():632818. PubMed ID: 33959007
[No Abstract] [Full Text] [Related]
6. Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients.
Ten Ham RMT; van Nuland M; Vreman RA; de Graaf LG; Rosing H; Bergman AM; Huitema ADR; Beijnen JH; Hövels AM
Value Health; 2021 Jan; 24(1):121-128. PubMed ID: 33431146
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance.
Zhang PF; Xie D; Li Q
BMC Cancer; 2021 Jan; 21(1):35. PubMed ID: 33413230
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer.
Gong CL; Hay JW
J Natl Compr Canc Netw; 2014 Oct; 12(10):1417-25. PubMed ID: 25313181
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial.
Zhan M; Zheng H; Yang Y; He Z; Xu T; Li Q
Cancer Manag Res; 2020; 12():12919-12926. PubMed ID: 33364840
[TBL] [Abstract][Full Text] [Related]
11. Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in
Li Y; Lin S; Zhong L; Luo S; Huang X; Huang X; Dong L; Xu X; Weng X
Pharmacogenomics; 2021 Aug; 22(13):809-819. PubMed ID: 34517749
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer in Japan.
Okumura H; Inoue S; Naidoo S; Holmstrom S; Akaza H
Jpn J Clin Oncol; 2021 Aug; 51(8):1319-1329. PubMed ID: 34037235
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective.
Chiang CL; So TH; Lam TC; Choi HCW
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):108-115. PubMed ID: 31273290
[TBL] [Abstract][Full Text] [Related]
14. A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
Sung WWY; Choi HCW; Luk PHY; So TH
Front Oncol; 2021; 11():627083. PubMed ID: 33718198
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden.
Polyzoi M; Ekman M; Reithmeier A; Jacob J; Karlsson E; Bertranou E; Linderholm B; Hettle R
Pharmacoecon Open; 2024 Mar; 8(2):277-289. PubMed ID: 38093030
[TBL] [Abstract][Full Text] [Related]
16. Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis.
Zeng X; Liu Q; Tan C; Wan X; Wang Y; Ma X
Front Pharmacol; 2022; 13():1003483. PubMed ID: 36339555
[No Abstract] [Full Text] [Related]
17. Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer From the US and Chinese Perspectives.
Wu Q; Liao W; Zhang M; Huang J; Zhang P; Li Q
Front Oncol; 2020; 10():1336. PubMed ID: 32850425
[No Abstract] [Full Text] [Related]
18. Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis.
Zhang PF; Xie D; Li Q
Front Public Health; 2021; 9():608375. PubMed ID: 33634066
[No Abstract] [Full Text] [Related]
19. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
[TBL] [Abstract][Full Text] [Related]
20. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
